The Big picture…

The Big Picture

Australian Cancer Research Foundation

.CANCERRESEARCH is a collaborative initiative facilitated by the Australian Cancer Research Foundation. Its focus is to bring together news, information, and leading opinion on cancer treatment, prevention, diagnosis and cure. We want you to be a part of the .CANCERRESEARCH community...

Please click here to learn more.




Explore our home site for an idea of what .CANCERRESEARCH has to offer.

> Information on different types of cancer
> Cancer research endeavours of the past and near future
> Ways you can get involved

Visit our home site home.cancerresearch


Targeting cells involved in aggressive prostate cancer

June 6, 2013

A new sub-group of cells that influences prostate cancer recurrence has been identified by researchers at Monash University.

The previously unidentified cells are present in the disease’s early stages, opening up new doors to develop a therapy which targets these cells and prevents the disease from progressing to an aggressive stage.

Prostate cancer is the most common form of cancer in men, claiming more than 3000 Australian lives and affecting up to 20,000 annually.

For advanced cases, the best available treatment involves drugs that deprive the tumour of the male hormones which cause it to grow (androgen-deprivation therapy) . In many cases, the tumour can become resistant to this treatment leaving the patient with both debilitating side-effects and an aggressive new form of the prostate cancer.

The new sub-group of cells identified by Monash researchers is involved in this very treatment resistance.

“The results indicate that these persistent cancer cells somehow differ from cancer cells that respond to androgen withdrawal, and are likely to be the precursor cells that lead to advanced androgen-resistant disease. We will now investigate how to effectively target these cells,” Professor Risbridger, who co-led the study said.

Professor Mark Frydenberg of the Monash Department of Surgery, and Chairman of the Department of Urology, Monash Health, said ultimately the findings could lead to additional therapies to increase the effectiveness of existing prostate cancer treatments.

“This new information suggests that potentially some of the powerful targeted therapies now being used for advanced prostate cancer may have a role to play in earlier localised cancers, especially those with high-risk features, and this hypothesis can be actively tested,” Professor Frydenberg said.

The world-class cancer genomics facility at Monash Institute of Medical Research, funded by a $1.6M ACRF grant, will greatly assist in the further development and follow-up of these studies.

Subscribe to our newsletter